Case Reports

Primary Localized Cutaneous Nodular Amyloidosis of the Thighs

Cutis. 2015 June;95(6):E24-E27

References

1. Sakuma TH, Hans-Filho G, Arita K, et al. Familial primary localized cutaneous amyloidosis in Brazil. Arch Dermatol. 2009;145:695-699.

2. Rodermund OE. On amyloidosis cutis nodularis atrophicans (Gottron 1950). at the same time a contribution to the classification of amyloidosis [in German]. Arch Klin Exp Dermatol. 1967;230:153-171.

3. Chapel TA, Birmingham DJ, Malinowski YE. Nodular primary localized cutaneous amyloidosis. Arch Dermatol. 1977;113:1248-1249.

4. Criado PR, Silva CS, Vasconcellos C, et al. Extensive nodular cutaneous amyloidosis: an unusual presentation. J Eur Acad Dermatol Venereol. 2005;19:481-483.

5. Touart DM, Sau P. Cutaneous deposition diseases. part I [published correction appears in J Am Acad Dermatol. 1998;39:1042]. J Am Acad Dermatol. 1998;39(2, pt 1):149-171; quiz 172-174.

6. Borrowman TA, Lutz ME, Walsh JS. Cutaneous nodular amyloidosis masquerading as a foot callus. J Am Acad Dermatol. 2003;49:307-310.

7. Fujimoto N, Yajima M, Ohnishi Y, et al. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis. J Invest Dermatol. 2002;118:479-484.

8. Clement CG, Truong LD. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum Pathol. 2014;45:1766-1772.

9. Lien MH, Railan D, Nelson BR. The efficacy of dermabrasion in the treatment of nodular amyloidosis. J Am Acad Dermatol. 1997;36(2, pt 2):315-316.

10. Taylor SC, Baker E, Grossman ME. Nodular vulvar amyloid as a presentation of systemic amyloidosis. J Am Acad Dermatol. 1991;24:139.

11. Northcutt AD, Vanover MJ. Nodular cutaneous amyloidosis involving the vulva. case report and literature review. Arch Dermatol. 1985;121:518-521.

12. Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sjögren’s syndrome: a review of the literature. J Dermatol. 2005;32:120-123.

13. Summers EM, Kendrick CG. Primary localized cutaneous nodular amyloidosis and CREST syndrome: a case report and review of the literature. Cutis. 2008;82:55-59.

14. Taniguchi Y, Horino T, Terada Y. Cutaneous amyloidosis associated with amyopathic dermatomyositis. J Rheumatol. 2009;36:1088-1089.

15. Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol. 2001;145:105-109.

16. Brownstein MH, Helwig EB. The cutaneous amyloidoses. I. localized forms. Arch Dermatol. 1970;102:8-19.

The histopathologic examination of PLCNA is characterized by large deposits of amorphous, sometimes fissured, pale, eosinophilic material in the papillary dermis, reticular dermis, and subcutaneous fat. The overlying epidermis may exhibit flattened rete ridges. Amyloid may occur within vessel walls and adnexal structures, sometimes in a ring surrounding individual fat cells. Clinically, the lesions of PLCNA may be indistinguishable from nodular deposits of amyloid occurring in primary systemic amyloidosis or myeloma-associated amyloidosis. Histopathologically, PLCNA usually has a variable infiltrate of plasma cells and lymphocytes at the periphery or within the amyloid deposits,⁶ but no single stain is highly sensitive and specific. Congo red–stained deposits showed salmon pink amorphous material or apple green birefringence with polarizing microscopy.⁸ Amyloid derived from immunoglobulin light chains, including cutaneous nodular amyloid, also stain positive for anti-human λ light chain antibody on immunohistochemistry. Additionally, amyloid can stain positively with methyl violet and crystal violet Gram stains, Picrosirius red, thioflavin T, Dylon, and periodic acid–Schiff stains.

Clinically, some PLCNA lesions can be removed via surgical excision or laser if they are cosmetically disfiguring or symptomatic. Other methods have been attempted to improve the appearance of the lesions, such as intralesional corticosteroids, cryotherapy, and dermabrasion,⁹ but they usually are not helpful and have a high rate of recurrence. Although PLCNA often is a benign cutaneous disorder and some cases of PLCNA could be reactive diseases rather than neoplastic ones, some patients may develop underlying systemic amyloidosis or even paraproteinemia.¹⁰ Northcutt and Vanover¹¹ indicated that systemic amyloidosis may be expected in less than 15% of 47 patients with localized cutaneous amyloidosis during follow-up by reviewing most of the related literature. Some cases may be associated with Sjögren syndrome (SJS), CREST (calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia) syndrome, dermatomyositis, and diabetes mellitus.^12-14 Polyclonal immunoglobulin amyloid has been reported only in PLCNA with SJS, which may be due to the fact that a certain population of SJS develops polyclonal B-cell proliferation and hyperglobulinemia.¹² Woollons and Black¹⁵ estimated the rate of progression of PLCNA to systemic amyloidosis to be only 7%, which is much lower than the rate in the literature by a large clinical follow-up study on PLCNA.¹⁶ However, all patients with PLCNA should have a systemic evaluation and should be advised to undergo long-term clinical follow-up to help prevent progression to systemic amyloidosis or plasma cell dyscrasia.